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Abstract
Background—Traditionally, norepinephrine has been associated with stress responses while
dopamine has been associated with reward. Both of these catecholamines are found within the bed
nucleus of the stria terminalis (BNST), a brain relay nucleus in the extended amygdala between
cortical/limbic centers, and the hypothalamic-pituitary-adrenal axis. Despite this colocalization,
little is known about subsecond catecholamine signaling in subregions of the BNST in response to
salient stimuli.
Methods—Changes in extracellular catecholamine concentration in subregions of the BNST in
response to salient stimuli were measured within the rat BNST using fast-scan cyclic voltammetry
at carbon-fiber microelectrodes.
Results—A discrete subregional distribution of release events was observed for different
catecholamines in this nucleus. In addition, rewarding and aversive tastants evoked inverse
patterns of norepinephrine and dopamine release in the BNST. An aversive stimulus, quinine,
activated noradrenergic signaling but inhibited dopaminergic signaling, while a palatable stimulus,
sucrose, inhibited norepinephrine while causing dopamine release.
Conclusions—This reciprocal relationship, coupled with their different time courses, can
provide integration of opposing hedonic states to influence response outputs appropriate for
survival.
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It is well established that a group of neuronal circuits form the brain ‘reward’ pathway, a
system that is activated during goal-directed behaviors such as acquisition and consumption
of palatable food(1). By analogy, another set of brain circuitry is activated by aversive
stimuli and their associated cues(2–4). A portion of both of these systems lies within the
extended amygdala, a group of telencephalic nuclei that act as relay centers where
information from descending cortical neurons is integrated with limbic afferents to evaluate
homeostasis(5). The extended amygdala includes the nucleus accumbens (NAc) shell, a
central structure in the brain reward pathway that receives a dense dopaminergic innervation
associated with motivation and reward processing(1). Indeed, dopamine release in the NAc
is immediately triggered by unexpected reward presentation(6,7) and it is suppressed
following delivery of an aversive substance(8).
The extended amygdala also includes the bed nucleus of the stria terminalis (BNST), a
catecholamine containing structure that has been linked with negative emotional states and
stress(4,9). The BNST consists of more than 12 anatomically distinct subnuclei. It serves as
a critical relay center and integrator between limbic structures (e.g. amygdala, hippocampus,
and medial prefrontal cortex) and the hypothalamic paraventricular nucleus (PVN)(10). Via
these pathways, excitatory and inhibitory input elicited by stress is conveyed to the
hypothalamic-pituitary adrenal (HPA) axis(11,12). The anterior BNST receives dense inputs
of both norepinephrine and dopamine. The dorsolateral (dl) BNST, that includes the oval
nucleus, receives dopaminergic innervation from the ventral tegmental area (VTA), dorsal
raphe nucleus and periaqueductal gray area but contains little norepinephrine(5,13,14). It is
noteworthy that the function of these dopamine neuron populations in the wake-sleep cycle
is different. Recent work suggests that the dopamine neurons in the ventrolateral
periaqueductal grey change their activity across sleep-wake periods and promote waking
while VTA dopamine neurons do not change its mean firing rate across the sleep-wake
cycle(15,16). In contrast to the dlBNST, the ventral (v) BNST, that includes the fusiform
nuclei, has a dense noradrenergic innervation from the nucleus of solitary tract (NST),
ventrolateral medulla (VM) and locus coeruleus (LC) cell groups, but little dopamine
content (17,18). The (dl) and (v)BNST subregions are interconnected with dense projections
from the oval nucleus to the fusiform nucleus and a lighter reciprocal connection. The
fusiform nucleus has a strong projection to the PVN by which it can activate the HPA
axis(10). However, little is known concerning catecholamine neurotransmission within the
BNST. While a few stressful stimuli such as fox odor(19) or morphine withdrawal(20) have
been shown to evoke norepinephrine increases within the BNST, the large size and slow
response of conventional chemical probes has impeded subsecond characterization of
behaviorally evoked catecholamine neurotransmission in the subregions of the BNST.
To evaluate brain processing during discrete rewarding and aversive events, we used intra-
oral delivery of tastants while measuring catecholamine responses with fast-scan cyclic
voltammetry at carbon-fiber microelectrodes, a methodology that enables subsecond
monitoring of extracellular catecholamines during behavior(21). Animals rapidly
differentiate aversive and palatable tastes and show different behavioral outputs(22). Rats
exhibit licking behavior during infusions of sucrose, a palatable tastant, and exhibit rejection
responses during infusions of quinine, an aversive tastant(23). Since rats typically avoid
aversive events, intra-oral deliveries allow evaluation of equal number of rewarding and
aversive events detected by the same sensory modality. We used this design to compare in
real time the responses to aversive and appetitive stimuli of dopamine and norepinephrine in
different subregions of the BNST.
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Male Sprague-Dawley rats (320–420g, Charles River, Wilmington, MA) were anesthetized
with ketamine hydrochloride (100 mg/kg) and xylazine hydrochloride (20 mg/kg) and
stereotaxic surgeries for electrochemical recordings were performed as described
previously(8). Small holes in the skull were drilled for reference (Ag/AgCl) and stimulating
electrodes as well as for carbon-fiber microelectrodes. A guide cannula (Bioanalytical
Systems, West Lafayette, IL, USA) for loading a micromanipulator containing a carbon-
fiber electrode on the day of the experiment was implanted above the vBNST (0.0 mm, 1.2
mm lateral from the bregma) or dlBNST (0.1 mm posterior, 1.6 mm lateral from the
bregma)(24). A bipolar, stainless-steel stimulating electrode (Plastics One, Roanoke, VA)
was placed in the ventral noradrenergic bundle (VNB) and VTA/substantial nigra(SN)
dopaminergic cell bodies (5.2 mm posterior, 1.0 mm lateral, 8.0–9.0 mm ventral). A
reference electrode was placed in the contralateral cortex. The implanted items were
permanently secured to the skull with dental cement.
Each intra-oral cannula for infusion of sucrose or quinine consisted of an approximately 6
cm length of PE-100 tubing which was flanged at one end with a Teflon washer(8). The
cannulas were inserted lateral to the first maxillary molar with the Teflon washer flush
against the molar on each side of the mouth. The other end was accessible via an incision at
the top of the head and held in place with a second Teflon washer.
Experimental Design
One week after recovery from surgery, rats were placed in a standard operant chamber and
voltammetric recordings were made. At the start of the behavioral session, white noise was
activated to control for potentially interfering ambient noise and the house light was turned
on to observe oro-facial responses. After a variable interval (1 to 2 min), a peristaltic pump
delivered ~200 µL of a tastant solution for 3.5 s through the intra-oral cannula. Rats received
multiple trials of sucrose followed by an equal number of trials of quinine at unpredictable
times to ensure comparable novelty and salience but opposing hedonic valence. Previous
studies showed that this design elicited strong and consistent behavioral differences in
hedonic expression with no evidence of anticipatory or conditioned responses(8), and the
dopamine response to intra-oral infusions is independent of the order of tastant delivery(8).
All animals received a brief rinse with distilled water after each oral infusion to prevent
lingering of the prior tastant in subsequent taste reactivity. After the tastant experiments,
selective dopamine and norepinephrine drugs were administered to verify that the recorded
signal was norepinephrine and/or dopamine. Following pharmacological agents, the tastants
were readministered in some animals. Each animal was run only on one day in a single
subregion of the BNST.
Voltammetric Procedures
Glass-encased, cylindrical carbon-fiber microelectrodes with an exposed length of 75 – 100
µm T-650 carbon fiber (5.1 µm in diameter) and reference electrodes were prepared as
described previously(25). Fast-scan cyclic voltammetry was computer-controlled. A
triangular scan (−0.4 to +1.3 V, 400V/s) was repeated every 100 ms. Data were digitized
and stored on a computer using software written in LABVIEW. Background-subtracted
cyclic voltammograms were obtained by digitally subtracting voltammograms collected
during stimulation from those collected during baseline recording. Voltammetric responses
were viewed as color plots with the abscissa as voltage, the ordinate as acquisition time, and
the current encoded in color. As the carbon-fiber microelectrode was used to lesion the
brain, thus marking the recording site, this precluded postcalibration of the electrode’s
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sensitivity (see below). Instead, we used postcalibration factors per carbon fiber area (6.9 ±
0.3 pA/(µM·µm2) for dopamine, 4.5 ± 0.2 pA/(µM·µm2) for norepinephrine) based on the
average response obtained from multiple electrodes as described in our previous study(26).
Each calibration factor was determined with 5 dopamine and norepinephrine concentration
standards. The calibration factors are scaled to the electrode length that varied between 75 ~
100 µm. Before the experiment, the length of the exposed carbon fiber was measured.
Histology
At the end of experiments, the recording sites were verified by electrolytic lesions by
applying constant current (20 µA for 10 s) to the carbon-fiber microelectrodes following
administration of urethane (1.2 g/kg)(18). The animals were subsequently euthanized with
an overdose of urethane. Brains were removed and stored in 10 % formaldehyde, and
coronally sectioned into 40 µm thick slices with a cryostat. The sections mounted on slides
were stained with 0.2 % thionin, and coverslipped before viewing under a light microscope.
Drugs and Reagents
In all animals, at least one drug selective for each catecholamine was administered
intraperitoneally(i.p.) to verify that the recorded signal was norepinephrine and/or dopamine
after both tastant experiments and their effects on electrically stimulated release were
evaluated. All drugs were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Desipramine-HCl (15 mg/kg), raclopride-HCl (2 mg/kg), and idazoxan-HCl (5 mg/kg) were
dissolved in saline. GBR 12909 (15 mg/kg) was dissolved in water and diluted in saline. The
doses of the drugs used are ones that are commonly used in microdialysis studies.
Data Analysis
The changes of basal catecholamine level by the tastants or electrically evoked
catecholamines over time were identified by a locally-written principal component
regression algorithm as descried earlier(27,28). A residual analysis procedure was used to
verify that the cyclic voltammograms of the trials being predicted were consistent with the
analyte cyclic voltammograms used for calibration. Any trials containing uncharacteristic
variance larger than 95% of the noise of the training set were discarded.
Clampfit 8.1 (Axon Instruments, Foster City, CA, USA) was used to analyze half-life (t1/2,
the time to descend from its maximum value to half of that value) as described in the
literature(18). Electrically stimulated catecholamine release was recorded every 4 min for 20
min prior to and for 30 min after intraperitoneally administration of drugs. To determine the
catecholamine concentration changes during tastant trials, data from each trial (−5 s before
and 20 s after infusion onset) were first background subtracted using the local minima in the
5 s prior to infusion onset as the baseline. Significant changes over time were evaluated
using average baseline (−5.0 to 0 s relative to infusion onset) and maximal evoked
catecholamine concentration during and after infusion (0.1 to 15 s). Mean values were
compared by using the two-tailed Student’s t-test to calculate the level of significance.
Statistical significance of difference in t±20nM (s) between dopamine and norepinephrine was
evaluated using two-way ANOVA with Bonferroni post-tests used to correct for multiple
comparisons. Statistical analysis employed GraphPad Software version 4.0 (San Diego, CA,
USA). P < 0.05 was regarded as statistically significant. Data are represented as mean ±
s.e.m.
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Depth profile of evoked catecholamine release in the BNST pathways
The subregions of the BNST targeted in this work are quite small (~200 µm across in the
horizontal plane for the dlBNST). However, as we showed in the vBNST of anesthetized
animals(18), evoked catecholamine release yields distinct responses as the position of the
electrode is lowered, and these responses can be used to guide microelectrode placement. In
these experiments, the detachable micromanipulator was implanted directly above the
targeted region, and the electrode was lowered 4.8 mm below the skull surface. A bipolar
stimulating electrode was implanted in the VTA/SN, the site of dopaminergic cell bodies, an
area that is traversed by the ventral noradrenergic bundle (VNB), a pathway originating in
the NST/VM cell groups. Thus, stimulation of this region evokes simultaneous
norepinephrine and dopamine release. The carbon-fiber microelectrode was lowered in
~0.15 mm increments, and catecholamine release was evoked at each position.
Figure 1A (left) shows the targeted track for measurements in the vBNST. In freely moving
animals, stimulated release above the BNST (6.0 mm) was not observed but as the carbon
fiber reached the dorsomedial (dm) BNST (6.3 mm) a small signal was seen during the
stimulation (Figure 1A, right). The cyclic voltammogram reveals that it arose from released
catecholamines. With further lowering, the electrode reached the anterior commissure where
stimulated release was not seen. Stimulated norepinephrine release was evoked at 7.5 mm,
the depth of the vBNST. Comparison of Figure 1A with the data presented in anesthetized
animals(18) the depth profiles are independent of anesthesia. While cyclic voltammograms
distinguish between catecholamines and their metabolites, they cannot discern dopamine
from norepinephrine(29). Thus, in our prior work we established that the predominant
catecholamine in this subregion is norepinephrine based upon tissue content,
Immunohistochemical results, and pharmacological results(18).
Figure 1B (left) shows the targeted track for the dlBNST. Stimulated release was not seen at
4.8 mm but at the depth of the medial caudate putamen (5.2 mm) and the dlBNST (6.5 mm)
dopamine release was evoked (Figure 1B, right). If the electrode was lowered further into
the anterior commissure, release was not evoked. Identical responses were obtained in
anesthetized animals. Pharmacological, anatomical, and electrochemical data in the
anesthetized animals established again that the predominant catecholamine detected in the
dlBNST was dopamine (Figure S1 in Supplement 1).
Dopamine signaling in the dlBNST in response to tastants
Once robust release sites were found in the dlBNST, we examined the effect of palatable
and aversive tastants on catecholamine release. Each naïve animal received repeated, small
volume (3.5 s, 200 µL), intra-oral infusions of sucrose, then an equal number of quinine
infusions. They were delivered at unpredictable times to ensure comparable novelty.
Intra-oral sucrose (0.3 M) infusions increased extracellular dopamine concentration as
shown in the average results from one animal (Figure 2A). In some trials, intra-oral sucrose
infusions evoked a rapid and significant elevation in dopamine concentration that started
during the infusion and then returned to baseline whereas in other trials no change was
observed (examples in Figure 2B). In response to intra-oral quinine (0.001 M) infusions,
however, dopamine concentrations decreased (averaged example from one animal in Figure
2C, individual trials in Figure 2D). The trial by trial variations with sucrose were not
apparent when results from all animals were averaged together (Figure S2A in Supplement
1). The average dopamine concentration changes in multiple rats following each tastant are
shown in Figure 3A. The average time for a 20 nM change following initiation of infusion
(t±20nM) was < 5s with both tastants (Figure 3B). Both the direction and the time course of
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the changes are similar to rapid dopamine signaling in response to these tastants in the NAc
shell(8).
To ensure verification of the dopamine detected in each experiment, several experiments
were undertaken. At each measurement site in the dlBNST, idazoxan, an α2-adrenergic
antagonist, and desipramine, a norepinephrine transporter inhibitor, did not alter the
maximal electrically evoked dopamine concentration ([DA], Figure 3C) nor its time to
return to half of its maximal concentration (t1/2, Figure 3D). In contrast, raclopride, a D2
antagonist, and GBR 12909, a dopamine transporter inhibitor, significantly increased both
[DA] and t1/2 of evoked release at all dlBNST sites. Subsequently, an electrolytic lesion was
made with the carbon-fiber microelectrode for histological identification (Figure S3A in
Supplement 1). Taken together, the cyclic voltammograms, coupled with the histological
and pharmacological results, confirmed that the signals reported from the dlBNST arise
from dopamine.
Norepinephrine signaling in the vBNST in response to tastants
In a different group of animals, we investigated norepinephrine responses in the vBNST to
the same intra-oral delivery of tastants. The responses were opposite to those observed for
dopamine in the dlBNST. Following sucrose infusions, the extracellular norepinephrine
concentration gradually decreased (example from one animal in Figure 4A and B), whereas
it increased following quinine delivery (example from the same animal in Figure 4C and D;
average norepinephrine concentration changes in multiple rats following each tastant in
Figure 5A). Mean norepinephrine concentration changes did not differ by trial number for
either tastant (Figure S2B in Supplement 1) despite trial by trial variation (Figure 4B, D).
The average t±20nM following tastant infusion in this region was ~ 9 s (Figure 5B), values
that are significantly longer than those for dopamine (t±20nM, F1, 21 = 45.7, P < 0.001,
compare Figure 3B and 5B). Confirming norepinephrine detection, idazoxan and
desipramine both significantly increased evoked [NE] and t1/2 (Figure 5C and D). However,
neither raclopride nor GBR 12909 significantly altered stimulated responses in this
subregion. Again, electrode placements were electrolytically marked and histologically
verified (Figure S3B in Supplement 1). The responses termed noradrenergic exclude those in
which the carbon-fiber microelectrode was outside the vBNST.
Pharmacological effects on BNST catecholamine signaling in response to tastants
Following pharmacological agents, the tastants were readministered in some animals. In the
dlBNST the dopaminergic response to sucrose was enhanced following raclopride, but little
change was seen in the response to quinine (examples in Figure S4 in Supplement 1). In the
vBNST, the noradrenergic response to sucrose was unaffected by idazoxan, whereas it was
amplified following quinine (examples in Figure S5 in Supplement 1). After administration
of both idazoxan and desipramine, the noradrenergic response to quinine was increased even
more. Evoked norepinephrine concentration lasted for a longer time in the vBNST than the
dopamine concentration in the dlBNST (Fig. 2 and 4), returning back to the pre-quinine
basal norepinephrine level within a minute (examples in Figure S6 in Supplement 1). After
administration of idazoxan and desipramine, increased norepinephrine in response to quinine
lasted longer than a minute. Once again, the increased norepinephrine concentration in
response to quinine clearly showed no change by trial number.
In eight recording sites, the pharmacological responses indicated that both norepinephrine
and dopamine contributed to the cyclic voltammetric signal (indicated by red triangles in
Figure S3 in Supplement 1). These sites were found in the border regions between the
dlBNST and dmBNST, and between vBNST and ventral pallidum. In four of these locations,
the signals were too small for evaluation of tastant responses. However, in the remaining
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sites, the response to tastants was intermediate between that expected for norepinephrine and
dopamine. An example set of responses at one of these sites at the boundary between
dlBNST and dmBNST is shown in Figure 6. Following intra-oral sucrose there was a
catecholamine concentration increase (mean in this animal of 10.1 ± 2.3 nM, n = 15 trials)
followed by a decrease (−14.0 ± 4.9 nM; Figure 6A) that fluctuated on a trial by trial basis
(Figure 6B). Following intra-oral quinine, the tastant first infused in this animal,
catecholamine(s) increased (Figure 6C and D, 20.5 ± 5.8 nM during 15 trials). Subsequently,
the presence of both catecholamines was confirmed since the amplitude and time course of
electrically evoked release was increased by administration of raclopride, and then further
increased following idazoxan (Figure 6E). Following the two antagonists, intra-oral sucrose
induced larger catecholamine increases (51.9 ± 6.8 nM, P < 0.0001 relative to predrug
responses) and the subsequent decline also appeared enhanced (−28.4 ± 4.9 nM, P < 0.05
relative to predrug responses). However, intra-oral quinine after the antagonists induced a
catecholamine increase that was indistinguishable from that before drugs in this region with
mixed contributions. Evidently, the composite signal from norepinephrine and dopamine,
although likely changed by the antagonist administration, summed to the same level.
Discussion
The data presented here provide the first subsecond measurements of catecholamines in the
BNST of an ambulatory rat. These measurements reveal an unanticipated reciprocal
relationship in the extracellular concentration changes of norepinephrine and dopamine in
response to aversive and palatable tastants. As previously established in anesthetized
animals, the signal in the vBNST is primarily due to norepinephrine(18), and, as shown here,
the predominant releasable catecholamine in the dlBNST is dopamine based on anatomical
and pharmacological evidence. The boundaries of these two BNST subnuclei are separated
by a microscopic distance (~150 µm). Nevertheless, the concentration changes of
norepinephrine and dopamine are directly opposite and have significantly different temporal
responses to the intra-oral delivery of palatable and aversive tastants. In the dlBNST,
dopamine changes occur during the infusion time of the tastant, decreasing in response to
quinine and increasing in response to sucrose. In contrast, the norepinephrine responses in
the vBNST are the reciprocal, significantly lag those for dopamine, and show prolonged
changes that exceed the 20 s measurement. Indeed, a cumulative decline in norepinephrine
dialysate concentration from the NAc has been reported some 20 min after initiation of
sucrose intake(30). Catecholamine responses to tastants also occur in other subregions of the
BNST but, when they overlap, their individual contributions cannot be resolved (Figure 6).
The observed, opposing catecholamine-concentration changes in response to appetitive and
aversive stimuli are consistent with prior single-unit recordings in regions afferent to the
BNST. Noradrenergic neurons in the locus coeruleus show increased activity with a variety
of stressors and during drug withdrawal(17,31) and decreased firing rates in response to
sucrose intake(32). In contrast, most dopaminergic neurons in the VTA show increased
firing on presentation of rewarding stimuli, but diminished firing on presentation of aversive
stimuli and during drug withdrawal(33–35). However, there are exceptions with a subset of
dopamine neurons that are excited by noxious stimuli(36). Previous electrophysiological and
neurochemical findings show that most dopamine neurons appear to encode a reward
prediction-error rule(37–39), but it does not appear that norepinephrine neuron firing
activity encodes an prediction error(37). Instead, norepinephrine neuronal signaling
regulates attention, arousal, and memory(40). Noradrenergic neuronal activity appears to be
elicited by conditioned stimuli, and tracks both the conditioned response and outcome of the
action(41,42). However, most of our knowledge of the function of norepinephrine neurons
comes from electrophysiological studies in the LC, whereas the majority of noradrenergic
input to the vBNST originates from NST/VM(12). While electrophysiological recordings
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provide a general view of the activity of dopaminergic and noradrenergic neurons, they do
not yield information on the specific release patterns of the catecholamines in their terminal
regions. This can be a critical shortcoming in understanding neurotransmitter actions
because chemical release can be regionally specific even though it originates from the same
group of neurons(43).
The small volume sensed by the carbon-fiber microelectrode makes it highly sensitive to
spatial fluctuations in the release from neurons. Our chemical measurements reveal that
dopamine-encoded information concerning rewarding and aversive stimuli that is
transmitted to the brain reward system is conveyed to the dlBNST in an identical form to
that previously reported for dopamine in another extended amygdala, the NAc shell(8). In
both brain regions the responses show that a population of dopamine nerve terminals are
excited by appetitive stimuli and silenced by aversive stimuli. The trial by trial variations of
dopamine or norepinephrine concentrations for sucrose or quinine data were not apparent
when results from all animals were averaged together (P > 0.05 for sucrose and quinine,
one-way repeated measures ANOVA) (Figure 2 and 4B, D). Identical fluctuations in release
amplitudes from trial to trial has been also observed for dopamine concentration changes
associated with repetitive responses to novel stimuli(44).
Accumulating evidence shows that different subregions of the BNST may play different or
even opposing roles in integrating and processing limbic information and can either excite or
inhibit HPA axis activity by neuronal modulation of the PVN(12,45). This is clearly true for
the two different subregions examined in this work. Both catecholamines modulate
glutamatergic synaptic transmission at target neurons in the BNST, but in opposite ways.
Dopamine in the dlBNST increases spontaneous glutamatergic transmission(46), while in
the vBNST norepinephrine causes a decrease in glutamatergic transmission(47). Thus, their
reciprocal responses to aversive and rewarding stimuli reinforce these actions. The
anatomical connections of these neuronal circuits are arranged to strengthen this reciprocal
relationship. For example, norepinephrine signaling enhances inhibition of BNST
projections to VTA, an action that is expected to decrease dopaminergic signaling(48).
Furthermore, norepinephrine engages a feed-forward system involving CRF that can further
activate behavioral responses to stressors(31). The net result of these reciprocal actions of
dopamine and norepinephrine is an excitation of the HPA axis in response to aversive
stimuli and an inhibition in response to rewarding stimuli. The significance of these
neurochemical signals is also suggested by the timing of their responses. The dopamine
system rapidly conveys information about reward, providing this signal on a timescale
needed for quick retrieval. In contrast, norepinephrine responses are delayed and prolonged,
providing a signal that is suitable for maintained avoidance of aversive stimuli.
Thus, our data are consistent with the view that the BNST functions as a reward-aversion
integrator, processing opposing hedonic states and influencing response outputs appropriate
for survival. Anatomical and physiological data had inferred such integration in the
BNST(45), and our results concerning catecholamine neurotransmission confirm these
expectations. We have restricted our analysis of the responses to the dlBNST and vBNST
because the two catecholamines give well resolved responses in these regions. However, our
recordings in other regions of the BNST indicate that the level of integration is even greater
in subnuclei where both neurotransmitters reside.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Electrically evoked catecholamine responses in the vBNST and dlBNST. (A) and (B) (left)
Diagram of the region examined at 0.0 mm from bregma(24). The dotted lines illustrate the
approximate path of the carbon-fiber microelectrode through the vBNST and dlBNST. (A)
and (B)(right) Evoked (60 Hz, 40 pulses, 150 µA) catecholamine concentrations recorded at
the depth indicated. The red bars under the current trace show the electrical stimulation time.
Inset: background-subtracted cyclic voltammogram measured during the indicated trace.
Abbreviations: CPu, caudate-putamen; AC, anterior commissure; dmBNST, dorsomedial
bed nucleus of the stria terminalis; VP, ventral pallidum; LV, lateral ventricle.
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Dopamine signaling in the dlBNST in response to palatable and aversive tastants. (A) Intra-
oral infusions of sucrose increase dopamine release. The upper trace is the average
dopamine concentration change over 15 trials in response to intraoral sucrose infusions in a
single animal (infusions during the red bar). The color plot shows the averaged cyclic
voltammograms collected during the 15 trials. Catecholamine concentration changes are
apparent in the color plots at the potential for its oxidation (~ +0.65 V, dotted white line) and
its reduction (~ −0.2 V, solid white line). (B) Trial-by-trial changes of dopamine
concentration from the animal shown in (A) in response to intra-oral sucrose infusion. (C)
Upper trace is the average dopamine concentration change over 15 trials in response to intra-
oral infusions of quinine in a single animal (infusions during the red bar). The color plot
shows the average of all of the cyclic voltammograms collected during the 15 trials in this
animal. (D) Trial-by-trial changes of dopamine concentration from the animal shown in (C)
in response to intraoral infusions of quinine. In (A) and (C) the mean is given by the solid
lines and ± s.e.m. is given by the dotted lines.
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Average concentration change and time course for dopamine in the dlBNST. (A) Maximal
dopamine concentration change measured in response to infused tastants (P < 0.005 for
sucrose, P < 0.01 for quinine). (B) Time for dopamine to change by 20 nM (t±20nM) after
initiation of tastant infusion. (C, D) Effect of idazoxan (IDA, 5 mg/kg), desipramine (DMI,
15 mg/kg), raclopride (RA, 2 mg/kg) and GBR 12909 (GBR, 15 mg/kg) on electrically
evoked dopamine release. (C) Maximal dopamine concentration ([DA]) and (D) time to
clear the released dopamine to half of its maximal concentration (t1/2). * Indicates
significantly different from control values (P < 0.05).
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Norepinephrine signaling in the vBNST in response to palatable and aversive tastants in a
single animal. (A) Intra-oral infusions of sucrose decrease norepinephrine release. The upper
trace is the average norepinephrine concentration change over 15 trials in response to intra-
oral sucrose infusions in a single animal (infusions during the red bar). The color plot shows
the averaged cyclic voltammograms collected during the 15 trials. White lines are as in
Figure 2(A). (B) Trial-by-trial changes of norepinephrine concentration from the animal
shown in (A) in response to intra-oral sucrose infusion. (C) Upper trace is the average
norepinephrine concentration change over 15 trials in response to intra-oral infusions of
quinine in a single animal (infusions during the red bar). The color plot shows the average of
all of the cyclic voltammograms collected during the 15 trials in this animal. (D) Trial-by-
trial changes of norepinephrine concentration from the animal shown in (C) in response to
intra-oral infusions of quinine. In (A) and (C) the mean is given by the solid lines and ±
s.e.m. is given by the dotted lines.
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Average concentration change and time course for norepinephrine in the vBNST. (A)
Maximal norepinephrine concentration change measured in response to infused tastants (p <
0.0001 for sucrose, P < 0.0001 for quinine). (B) Time for 20 nM norepinephrine changes to
occur (t±20nM) after initiation of tastant infusion. (C, D) Effect of idazoxan (IDA, 5 mg/kg),
desipramine (DMI, 15 mg/kg), raclopride (RA, 2 mg/kg) and GBR 12909 (GBR, 15 mg/kg)
on electrically evoked norepinephrine release. (C) Maximal evoked norepinephrine
concentration ([NE]). (D) half-decay time (t1/2).
* Indicates significantly different from control values (P < 0.05).
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Catecholamine signaling at a single location in the border of the dl- and dmBMST. (A) The
upper trace is the average catecholamine concentration change over 15 trials in response to
intra-oral sucrose infusions in a single animal (infusions during the red bar). The color plot
shows the averaged cyclic voltammograms collected during the 15 trials. (B) Trial-by-trial
changes of catecholamine concentration from the animal shown in (A) in response to intra-
oral sucrose infusion. (C) Upper trace is the average catecholamine concentration change
over 15 trials in response to intra-oral infusions of quinine in a single animal (infusions
during the red bar). The color plot shows the average of all of the cyclic voltammograms
collected during the 15 trials in this animal. (D) Trial-by-trial changes of dopamine
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concentration from the animal shown in (C) in response to intra-oral infusions of quinine. In
(A) and (C) the mean is given by the solid lines and ± s.e.m. is given by the dotted lines. (E)
Responses in this location to electrical stimulation before and after administration of the RA,
(predrug [CA] = 167 ± 7 nM, 20 min post RA [CA] = 236 ± 5 nM P < 0.005, 3 trials) and
IDA ([CA] = 257 ± 7 nM 50 min after RA, 20 min after IDA [CA] = 414 ± 4 nM, P <
0.0001, 3 trials). (F) Average concentration traces (mean ± s.e.m. denoted by solid and
broken lines, respectively) following intra-oral sucrose (upper, n = 18 infusions) and quinine
(lower, n = 14 infusions) after administration of RA and IDA. (G) An electrolytic lesion
(denoted by broken red circle) in the BNST at the site where these recordings were made.
Abbreviations: CPu, caudate-putamen; AC, anterior commissure; VP, ventral pallidum; LV,
lateral ventricle; dm, dorsomedial bed nucleus of the stria terminalis; dl, dorsolateral bed
nucleus of the stria terminalis.
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